PT3021838T - Tratamento para a obesidade - Google Patents

Tratamento para a obesidade

Info

Publication number
PT3021838T
PT3021838T PT148257249T PT14825724T PT3021838T PT 3021838 T PT3021838 T PT 3021838T PT 148257249 T PT148257249 T PT 148257249T PT 14825724 T PT14825724 T PT 14825724T PT 3021838 T PT3021838 T PT 3021838T
Authority
PT
Portugal
Prior art keywords
obesity
treatment
Prior art date
Application number
PT148257249T
Other languages
English (en)
Original Assignee
Sk Biopharmaceuticals Co Ltd
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd, Jazz Pharmaceuticals Ireland Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of PT3021838T publication Critical patent/PT3021838T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT148257249T 2013-07-18 2014-07-18 Tratamento para a obesidade PT3021838T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361847593P 2013-07-18 2013-07-18

Publications (1)

Publication Number Publication Date
PT3021838T true PT3021838T (pt) 2020-09-01

Family

ID=52344067

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148257249T PT3021838T (pt) 2013-07-18 2014-07-18 Tratamento para a obesidade

Country Status (12)

Country Link
US (6) US9226910B2 (pt)
EP (1) EP3021838B1 (pt)
JP (2) JP6529495B2 (pt)
KR (1) KR102309836B1 (pt)
CN (2) CN110638804A (pt)
CA (1) CA2917702A1 (pt)
DK (1) DK3021838T3 (pt)
ES (1) ES2812586T3 (pt)
PL (1) PL3021838T3 (pt)
PT (1) PT3021838T (pt)
TW (1) TW201919605A (pt)
WO (1) WO2015010014A1 (pt)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110638804A (zh) * 2013-07-18 2020-01-03 爵士制药国际Iii有限公司 治疗肥胖
TWI655179B (zh) * 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10661504B2 (en) * 2015-03-02 2020-05-26 Funfare, Llc Three dimensional printer and cartridge
EP3509582B1 (en) 2016-09-06 2023-12-20 Axsome Malta Ltd. Solvate form of (r)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
MY202185A (en) 2016-10-06 2024-04-15 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol compounds and uses therof
CA3065522A1 (en) 2017-06-02 2018-12-06 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
AU2018312328B2 (en) 2017-07-31 2022-12-15 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
EP4033068A1 (en) 2021-01-25 2022-07-27 Welltec A/S Downhole wireline tool string

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ285829B6 (cs) 1993-06-10 1999-11-17 Eli Lilly And Company Použití derivátu tetrahydrobenz [c,d]indolu pro výrobu farmaceutického prostředku vhodného pro ošetřování sexuální dysfunkce
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) * 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
PT873308E (pt) 1996-10-10 2002-06-28 Sk Corp Compostos de o-carbamoil-fenilalaninol seus sais farmaceuticamente uteis e processo para a preparacao dos mesmos
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
CA2587481A1 (en) * 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
BRPI0613697A2 (pt) 2005-06-08 2011-01-25 Sk Holdings Co Ltd tratamento de distúrbios de sono-vigìlia
ES2344469T3 (es) 2005-06-22 2010-08-27 Sk Holdings Co., Ltd. Tratamiento de disfuncion sexual.
EP1928451B1 (en) 2005-07-26 2011-12-28 SK Biopharmaceuticals Co., LTD Methods for treating substance-related disorders
KR20090082213A (ko) 2006-10-13 2009-07-29 얀센 파마슈티카 엔.브이. 페닐알킬아미노 카바메이트 조성물
CA2622696A1 (en) * 2007-11-05 2009-05-05 Diane Mcintosh Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs
WO2009129181A1 (en) 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Propanediol-dicarbamate derivatives
CN102481274A (zh) * 2009-06-22 2012-05-30 爱思开生物制药株式会社 治疗或预防疲劳的方法
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
JP5761173B2 (ja) 2010-03-04 2015-08-12 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
AU2014248849B2 (en) 2013-03-13 2018-08-30 Jazz Pharmaceuticals Ireland Limited Treatment of cataplexy
CN110638804A (zh) * 2013-07-18 2020-01-03 爵士制药国际Iii有限公司 治疗肥胖

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11826335B2 (en) 2016-07-22 2023-11-28 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en) 2016-07-22 2024-02-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Also Published As

Publication number Publication date
CN105873576B (zh) 2019-07-19
US20190099395A1 (en) 2019-04-04
ES2812586T3 (es) 2021-03-17
US11497725B2 (en) 2022-11-15
US20150025136A1 (en) 2015-01-22
US10105341B2 (en) 2018-10-23
TW201919605A (zh) 2019-06-01
DK3021838T3 (da) 2020-08-24
EP3021838A1 (en) 2016-05-25
CA2917702A1 (en) 2015-01-22
EP3021838B1 (en) 2020-05-27
CN105873576A (zh) 2016-08-17
JP6824315B2 (ja) 2021-02-03
US20170340596A1 (en) 2017-11-30
JP2019089859A (ja) 2019-06-13
US9226910B2 (en) 2016-01-05
US9649291B2 (en) 2017-05-16
JP2016532679A (ja) 2016-10-20
KR20160032127A (ko) 2016-03-23
US20160081970A1 (en) 2016-03-24
CN110638804A (zh) 2020-01-03
EP3021838A4 (en) 2017-01-18
US20210077450A1 (en) 2021-03-18
KR102309836B1 (ko) 2021-10-12
WO2015010014A1 (en) 2015-01-22
PL3021838T3 (pl) 2021-03-08
JP6529495B2 (ja) 2019-06-12
US20230172896A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
IL244869A0 (en) Device treatment
PT3021838T (pt) Tratamento para a obesidade
HK1220104A1 (zh) 用於醫治肥胖的胃內裝置
EP2946736A4 (en) TREATMENT DEVICE
GB201302789D0 (en) Apparatus
GB201300928D0 (en) Apparatus
GB2512025B (en) Surface treatment device
PL3079743T3 (pl) Urządzenie
HK1215164A1 (zh) 處理方法
GB201304872D0 (en) Treatment
EP2948669A4 (en) FUEL TREATMENT APPARATUS
GB201308440D0 (en) Therapeutic
IL245463B (en) valve
GB201310755D0 (en) Therapy
HK1216391A1 (zh) 組合治療
GB201318668D0 (en) Sonosensitive therapeutic
GB201312419D0 (en) Manipulation treatment apparatus
GB2509800B (en) Splint
GB201307310D0 (en) Treatment
GB201316521D0 (en) Therapeutic apparatus
GB201310529D0 (en) Traysealing apparatus
GB2509801B (en) Splint
GB201304811D0 (en) Novel treatment for hypertension
GB201321115D0 (en) Treatment
GB201309238D0 (en) Treatment